Global Blood Therapeutics Inc is a clinical-stage biopharmaceutical company in the United States. Its major focus lies on developing therapeutics for the treatment of blood-based disorders such as red blood cell sickling.
$26.17 +0.71 (2.79%)
As of 05/27/2022 15:59:56 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.